{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:23:10Z","timestamp":1788121390056,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008539","name":"Kinjo Gakuin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10147-025-02804-3","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T22:39:22Z","timestamp":1749076762000},"page":"1602-1609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of cancer type differences on chemotherapy-induced nausea and vomiting (CINV) incidence in oxaliplatin-based regimens for gastric and colorectal cancer: a retrospective study"],"prefix":"10.1007","volume":"30","author":[{"given":"Nanaho","family":"Hiraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8166-8165","authenticated-orcid":false,"given":"Yosuke","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seira","family":"Nishibe-Toyosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenichi","family":"Morise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2804_CR1","unstructured":"Japanese Society for Cancer of the Colon and Rectum (2024) Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2024 for the treatment of colorectal cancer. Kanehara Publishing, Tokyo. https:\/\/www.jsccr.jp\/guideline\/data\/guide_doctor_2024.pdf Accessed 28 Jan 2025"},{"key":"2804_CR2","volume-title":"Japanese gastric cancer treatment guidelines 2025","author":"Japanese Gastric Cancer Association","year":"2025","unstructured":"Japanese Gastric Cancer Association (2025) Japanese gastric cancer treatment guidelines 2025, 7th edn. Kanehara & Co., Ltd., Tokyo","edition":"7"},{"key":"2804_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol 26:141\u2013148. https:\/\/doi.org\/10.1093\/annonc\/mdu472","journal-title":"Ann Oncol"},{"key":"2804_CR4","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, D\u00edaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006\u20132012. https:\/\/doi.org\/10.1200\/JCO.2007.14.9898","journal-title":"J Clin Oncol"},{"key":"2804_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","volume":"25","author":"HJ Schmoll","year":"2007","unstructured":"Schmoll HJ, Cartwright T, Tabernero J et al (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25:102\u2013109. https:\/\/doi.org\/10.1200\/JCO.2006.08.1075","journal-title":"J Clin Oncol"},{"key":"2804_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (Classic): a phase 3 open-label, randomised controlled trial. Lancet 379:315\u2013321. https:\/\/doi.org\/10.1016\/S0140-6736(11)61873-4","journal-title":"Lancet"},{"key":"2804_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"2804_CR8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"N Boku","year":"2019","unstructured":"Boku N, Ryu MH, Kato K et al (2019) Safety and efficacy of nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 30:250\u2013258. https:\/\/doi.org\/10.1093\/annonc\/mdy540","journal-title":"Ann Oncol"},{"key":"2804_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401:1655\u20131668. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7","journal-title":"Lancet"},{"key":"2804_CR10","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29:2133\u20132141. https:\/\/doi.org\/10.1038\/s41591-023-02465-7","journal-title":"Nat Med"},{"key":"2804_CR11","unstructured":"Japanese Society of Medical Oncology (2023) Antiemetic therapy guidelines. http:\/\/www.jsco-cpg.jp\/antiemetic-therapy\/Accessed Accessed 28 Jan 2025"},{"key":"2804_CR12","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","volume":"14","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Takahari D, Matsumoto H et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14:1278\u20131286. https:\/\/doi.org\/10.1016\/S1470-2045(13)70490-X","journal-title":"Lancet Oncol"},{"key":"2804_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115\u2013124. https:\/\/doi.org\/10.1016\/S1470-2045(08)70313-9","journal-title":"Lancet Oncol"},{"key":"2804_CR14","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.21873\/anticanres.11254","volume":"36","author":"A Suzuki","year":"2016","unstructured":"Suzuki A, Kobayashi R, Fujii H et al (2016) Control of nausea and vomiting in patients with colorectal cancer receiving chemotherapy with moderate emetic risk. Anticancer Res 36:6527\u20136533. https:\/\/doi.org\/10.21873\/anticanres.11254","journal-title":"Anticancer Res"},{"key":"2804_CR15","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura J, Satoh T, Fukunaga M et al (2015) Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51:1274\u20131282. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.024","journal-title":"Eur J Cancer"},{"key":"2804_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00520-023-08222-3","volume":"32","author":"F Scott\u00e9","year":"2023","unstructured":"Scott\u00e9 F, Schwartzberg L, Iihara H et al (2023) 2023 updated MASCC\/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Support Care Cancer 32:45. https:\/\/doi.org\/10.1007\/s00520-023-08222-3","journal-title":"Support Care Cancer"},{"key":"2804_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/00365528309181562","volume":"18","author":"O Lawaetz","year":"1983","unstructured":"Lawaetz O, Blackburn AM, Bloom SR et al (1983) Gut hormone profile and gastric emptying in the dumping syndrome. A hypothesis concerning the pathogenesis. Scand J Gastroenterol 18:73\u201380. https:\/\/doi.org\/10.3109\/00365528309181562","journal-title":"Scand J Gastroenterol"},{"key":"2804_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5603\/njo.100022","volume":"74","author":"E Grochowska","year":"2024","unstructured":"Grochowska E, Gazi A, Surwi\u0142\u0142o-Snarska A et al (2024) Nutritional problems of patients after gastrectomy and the risk of malnutrition. NOWOTWORY J Oncol 74:226\u2013231. https:\/\/doi.org\/10.5603\/njo.100022","journal-title":"NOWOTWORY J Oncol"},{"key":"2804_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2020.00329","volume":"11","author":"ASM Mosa","year":"2020","unstructured":"Mosa ASM, Hossain AM, Lavoie BJ et al (2020) Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol 11:329. https:\/\/doi.org\/10.3389\/fphar.2020.00329","journal-title":"Front Pharmacol"},{"key":"2804_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K et al (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104:711\u2013717. https:\/\/doi.org\/10.1111\/cas.12146","journal-title":"Cancer Sci"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02804-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02804-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02804-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T07:37:16Z","timestamp":1753429036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02804-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2804"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02804-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yosuke Ando received honoraria for lectures from Chugai Pharm., Taiho Pharm., and Eisai and Takata Pharms. Kenji Kawada received honoraria for lectures from Novartis, Eisai and Chugai Pharm. Kenji Kawada received research funding from Chugai Pharm. and Abbott Japan LLC. Koichi Suda has no commercial or financial involvement construed as conflicts of interest regarding this article. Koichi Suda received funding from Sysmex Co. for the Collaborative Laboratory for Research and Development in Advanced Surgical Intelligence, Fujita Health University, outside this work. Koichi Suda also received research funding from Sysmex Co. and scholarship donations from Medicaroid, Inc., outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethical Review Board of Fujita Health University (Approval Number: HM22-030). All procedures involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Declaration of Helsinki, as revised in 2013, or with comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This was a retrospective study. The need for informed consent was waived due to the use of an opt-out approach.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}